A Phase 2 interventional study of Placebo and Leronlimab (700mg) in Coronavirus Disease 2019, sponsored by CytoDyn, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-01-04.
Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 672nd largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 64th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.
CytoDyn, Inc. has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.
The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period.
A total of 75 subjects will be randomized 2:1 in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection as defined below:
Mild (uncomplicated) Illness:
Moderate Illness:
Exclusion Criteria:
Any uncontrolled active systemic infection requiring admission to an intensive care unit (ICU); Note: Subjects infected with chronic virus or virus will be eligible for the study if they have no signs of hepatic decompensation.
Note: Subjects infected with -1 will be eligible for the study with undetectable viral load and are on a stable ART regimen. Investigators are required to review the subjects' medical records to confirm HIV-1 RNA suppression within the previous 3 months.
Note: Empirical antibiotic treatment for secondary bacterial infections is allowed during the course of study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The placebo comparator consists of the formulation buffer for leronlimab, i.e., the placebo is the same as the active arm without leronimab. The placebo is presented in the same container closure at the same fill volume as the active (nominal 1mL fill volume). The formulation buffer contains histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.
Drug: Placebo
Each vial of active contains 175mg of leronlimab at a concentration of 175mg/ml (nominal 1mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections.
Drug: Leronlimab (700mg)
Placebo
Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Also known as: PRO 140
Mean Change From Baseline in Total Symptom Score
Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough) by count of patients showing improvement, no change or worsened. Note: The total score per patient ranges from 0 to 12 points. Each symptom is graded from 0 to 3. \[0=none, 1=mild, 2=moderate, and 3=severe\]. Higher scores mean a worse outcome. A negative change from baseline shows an improvement in symptom score.
Time frame: Clinical Improvement will be assessed at baseline and at EOT (day 14).
Time to Clinical Resolution (TTCR)
Defined as the time from initiation of study treatment to the resolution of clinical symptoms (fever, myalgia, dyspnea, cough). Data presented how the number of days at which a certain percentage of patients achieve resolution of symptoms, i.e., 50% of patients on placebo saw resolution of symptoms in 15 days, and 15 days for patients on leronlimab. The hazard ratio was 0.781, 95% Confidence Interval 0.43, 1.41 and the p-value was 0.4138. TTCR is defined as the duration from date of first exposure to treatment to the first occurrence of total symptom score equals 0.
Time frame: Time (in days) from initiation of study treatment until resolution of clinical symptoms (fever, myalgia, dyspnea and cough).
Incidence of Hospitalization
Number of patients requiring hospitalization
Time frame: From visit 2 (day 0) through day 14 (in days)
Duration (Days) of Hospitalization
Duration of hospitalization in days
Time frame: Total duration of hospitalization between visit 2 (day 0) in days and end of treatment
Incidence of Mechanical Ventilation
Incidence of mechanical ventilation supply
Time frame: Total duration of mechanical ventilation since visit 2 (day 0) (days)
Duration of Mechanical Ventilation Supply
Duration (days) of mechanical ventilation supply
Time frame: Duration of mechanical ventilation since visit 2 (day 0) (days
Incidence of Oxygen Use
Incidence of oxygen use over course of treatment
Time frame: Use of oxygen since visit 2 (day 0) to end of treatment
Duration of Oxygen Use
Duration of oxygen use in days
Time frame: Total duration of oxygen use since visit 2 (day 0) to EOT (day 14) (days)
Mortality at Day 14
Incidence of mortality at day 14
Time frame: Mortality at EOT (day 14)
Time to Return to Normal Activity
Time to return to normal activity from initiation of study treatment defined as duration from date of first exposure to treatment to the first occurrence of ordinal scale equals "not hospitalized, no limitations of activities"
Time frame: Date of first exposure to treatment to the first occurrence of ordinal scale equals "not hospitalized, no limitations of activities"
Change From Baseline in National Early Warning Score 2 (NEWS2) to Day 3, 7 and 14
NEWS2 is an assessment based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness) developed by the Royal College of Physicians (https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2). Respiratory rate (bpm) scores 0-3; Sp02 (on room air or suppl) scores 0-3; SpO2 (hypercapnic resp failure) scores 0-3; room air or supplemental O2 scores 0 (room) or 2 (suppl); temperature - scores 0-3; systolic BP scores 0-3; pulse (bpm) scores 0-3; consciousness - alert (score 0) vs. new onset confusion (score 3). The total possible score ranges from 0 to 20. The higher the score the greater the clinical risk. Higher scores indicate the need for escalation, medical review and possible clinical intervention and more intensive monitoring. Change shown is positive or negative from baseline, with a negative number indicating improvement (i.e., a decrease in total score).
Time frame: Baseline to Day 3, 7 and 14
Mean Change in Percent Oxygen Saturation From Baseline to Days 3, 7 and 14
Mean change in percent oxygen saturation from baseline to Days 3, 7 and 14 for patients with paired values
Time frame: Mean change in percent oxygen saturation from baseline to Days 3, 7 and 14
Change From Baseline in the Patient's Health Status on a 7-category Ordinal Scale on Days 3, 7 and 14
A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. Lower scores mean a worse outcome.
Time frame: Assessments performed Day 0 (first treatment is Visit 2, day 0), Visit 3 (3+/- 1 day after first treatment) Visit 4 (second treatment, 7+/- 1 day from V2, day7) and end of treatment (7+/- 1 day from V4, day 14)
Change in Size of Lesion Area by Chest Radiograph or CT
Change in size of lesion area by chest radiograph or CT - exploratory endpoint
Time frame: Day 14
Change From Baseline in Serum Cytokine and Chemokine Levels
Change from baseline in serum cytokine and chemokine levels at day 3, day 7 and day 14
Time frame: Days 3, 7, and 14
Change From Baseline in CCR5 Receptor Occupancy Levels for Tregs and Macrophages
Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages at day3, day 7 and day 14
Time frame: Days 3, 7, and 14
Change From Baseline in CD3+, CD4+ and CD8+ T Cell Count
Change from baseline in CD3+, CD4+ and CD8+ T cell count at day 3, day 7 and day 14
Time frame: Days 3, 7, and 14
Participants were enrolled at study sites in the United States. The first participant was randomized on 30-Apr-2020. Data submitted represent analysis performed on data collected after all patients completed the Follow UP period.
| Milestone | Placebo | 700mg Leronlimab |
|---|---|---|
| Started | 29 | 57 |
| Completed | 17 | 33 |
| Not completed | 12 | 24 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Protocol violation | 4 | 6 |
| Withdrew: Missing | 3 | 9 |
| Withdrew: Withdrawal by subject | 0 | 4 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Did not start treatment | 1 | 1 |
| Withdrew: Patient did not complete visits 3-6 | 0 | 1 |
Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough) by count of patients showing improvement, no change or worsened. Note: The total score per patient ranges from 0 to 12 points. Each symptom is graded from 0 to 3. \[0=none, 1=mild, 2=moderate, and 3=severe\]. Higher scores mean a worse outcome. A negative change from baseline shows an improvement in symptom score.
| units on a scale | Placebo | 700mg Leronlimab |
|---|---|---|
| Mean Change From Baseline in Total Symptom Score | -3.4 ± 3.19 | -3.5 ± 3.03 |
Defined as the time from initiation of study treatment to the resolution of clinical symptoms (fever, myalgia, dyspnea, cough). Data presented how the number of days at which a certain percentage of patients achieve resolution of symptoms, i.e., 50% of patients on placebo saw resolution of symptoms in 15 days, and 15 days for patients on leronlimab. The hazard ratio was 0.781, 95% Confidence Interval 0.43, 1.41 and the p-value was 0.4138. TTCR is defined as the duration from date of first exposure to treatment to the first occurrence of total symptom score equals 0.
| days | Placebo | 700mg Leronlimab |
|---|---|---|
| 25% subjects | 5 | 8 |
| 50% subjects | 15 | 15 |
| 75% subjects | 15 | 15 |
Number of patients requiring hospitalization
| participants | Placebo | 700mg Leronlimab |
|---|---|---|
| None | 11 | 22 |
| 1 time | 14 | 33 |
| 2 times | 3 | 1 |
Duration of hospitalization in days
| days | Placebo | 700mg Leronlimab |
|---|---|---|
| Duration (Days) of Hospitalization | 2.0 ± 3.19 | 2.1 ± 3.83 |
Incidence of mechanical ventilation supply
| Participants | Placebo | 700mg Leronlimab |
|---|---|---|
| None | 27 | 55 |
| 1 Time | 1 | 1 |
Duration (days) of mechanical ventilation supply
| days | Placebo | 700mg Leronlimab |
|---|---|---|
| Duration of Mechanical Ventilation Supply | 0.4 ± 1.96 | 0.2 ± 1.00 |
Incidence of oxygen use over course of treatment
| Participants | Placebo | 700mg Leronlimab |
|---|---|---|
| None | 22 | 47 |
| One time | 5 | 6 |
| Two times | 1 | 2 |
| Three times | 0 | 1 |
Duration of oxygen use in days
| days | Placebo | 700mg Leronlimab |
|---|---|---|
| Duration of Oxygen Use | 0.8 ± 2.81 | 0.9 ± 2.98 |
Incidence of mortality at day 14
| Participants | Placebo | 700mg Leronlimab |
|---|---|---|
| Mortality at Day 14 | 0 | 0 |
Time to return to normal activity from initiation of study treatment defined as duration from date of first exposure to treatment to the first occurrence of ordinal scale equals "not hospitalized, no limitations of activities"
| days | Placebo | 700mg Leronlimab |
|---|---|---|
| 25th percentile pts return to normal | 4.0 | 5.0 |
| 50th percentile pts return to normal | 8.0 | 8.0 |
| 75th percentile pts return to normal | 9.0 | 15.0 |
NEWS2 is an assessment based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness) developed by the Royal College of Physicians (https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2). Respiratory rate (bpm) scores 0-3; Sp02 (on room air or suppl) scores 0-3; SpO2 (hypercapnic resp failure) scores 0-3; room air or supplemental O2 scores 0 (room) or 2 (suppl); temperature - scores 0-3; systolic BP scores 0-3; pulse (bpm) scores 0-3; consciousness - alert (score 0) vs. new onset confusion (score 3). The total possible score ranges from 0 to 20. The higher the score the greater the clinical risk. Higher scores indicate the need for escalation, medical review and possible clinical intervention and more intensive monitoring. Change shown is positive or negative from baseline, with a negative number indicating improvement (i.e., a decrease in total score).
| score on a scale | Placebo | 700mg Leronlimab |
|---|---|---|
| Change from Baseline to Day 3 | 0.0 ± 0.87 | -0.3 ± 1.67 |
| Change from Baseline to Day 7 | -0.2 ± 1.27 | -0.3 ± 2.24 |
| Change from Baseline to Day 14 | -0.2 ± 1.06 | -0.4 ± 2.42 |
Mean change in percent oxygen saturation from baseline to Days 3, 7 and 14 for patients with paired values
| Mean change in % O2 sat | Placebo | 700mg Leronlimab |
|---|---|---|
| Mean change from Baseline to Day 3 of percent oxygen saturation | 0.3 ± 1.91 | -0.1 ± 2.0 |
| Mean change from Baseline to Day 7 of percent oxygen saturation | 0.4 ± 2.08 | 0.00 ± 2.30 |
| Mean change from Baseline to Day 14 of percent oxygen saturation | 0.6 ± 1.73 | 0.3 ± 2.39 |
A 7-category ordinal scale of patient health status ranges from: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities. Lower scores mean a worse outcome.
| units on a scale | Placebo | 700mg Leronlimab |
|---|---|---|
| Mean change from baseline at day 3 | 0.4 ± 0.80 | 0.5 ± 0.75 |
| Mean change from baseline at day 7 | 1.1 ± 0.78 | 0.7 ± 0.99 |
| Mean change from baseline at day 14 | 1.2 ± 0.75 | 1.0 ± 1.13 |
Change in size of lesion area by chest radiograph or CT - exploratory endpoint
Results for this outcome have not been posted.
Change from baseline in serum cytokine and chemokine levels at day 3, day 7 and day 14
Results for this outcome have not been posted.
Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages at day3, day 7 and day 14
Results for this outcome have not been posted.
Change from baseline in CD3+, CD4+ and CD8+ T cell count at day 3, day 7 and day 14
Results for this outcome have not been posted.
Collected over Study drug was administered at Visit 2 (day 0) and visit 4 (day 7). Adverse events were assessed during the course of treatment and during the follow up period i.e., 2 weeks (visit 6) and 4 weeks (visit 7) after end of treatment. Therefore adverse events were assessed over a period of 5 weeks (visit 2 to visit 7).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/28 (0%) | 6/28 (21.4%) | 12/28 (42.9%) |
| 700mg Leronlimab | 1/56 (1.8%) | 5/56 (8.9%) | 7/56 (12.5%) |
| Event | Placebo | 700mg Leronlimab |
|---|---|---|
| Chest PainGeneral disorders | 2/28 | 0/56 |
| Atrial FibrillationCardiac disorders | 1/28 | 0/56 |
| Mitral Valve IncompetenceCardiac disorders | 1/28 | 0/56 |
| Abdominal PainGastrointestinal disorders | 1/28 | 0/56 |
| Swelling faceGeneral disorders | 1/28 | 0/56 |
| DehydrationMetabolism and nutrition disorders | 1/28 | 0/56 |
| HypoaesthesiaNervous system disorders | 1/28 | 0/56 |
| respiratory distressRespiratory, thoracic and mediastinal disorders | 1/28 | 0/56 |
| HypotensionVascular disorders | 1/28 | 0/56 |
| DeathGeneral disorders | 0/28 | 1/56 |
| Event | Placebo | 700mg Leronlimab |
|---|---|---|
| Muscular weaknessMusculoskeletal and connective tissue disorders | 4/28 | 0/56 |
| FatigueGeneral disorders | 2/28 | 1/56 |
| PneumoniaInfections and infestations | 2/28 | 0/56 |
| DiarrhoeaGastrointestinal disorders | 2/28 | 0/56 |
| C-reactive protein increasedInvestigations | 1/28 | 3/56 |
| Urinary Tract InfectionInfections and infestations | 1/28 | 3/56 |
The Modified Intent-to-Treat (mITT) population is defined as the set of subjects who have received at least one dose of leronlimab or placebo and is population used for the analysis of efficacy parameters or measurements. The Safety Population includes all subjects who received at least one dose of leronlimab or placebo. This population was used for the analysis of safety parameters or measurements. There were 84 subjects in the MITT and Safety Population.
| Age, Categorical(Participants) | Placebo | 700mg Leronlimab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 42 | 63 |
| >=65 years | 7 | 14 | 21 |
| Age, Continuous(years) | Placebo | 700mg Leronlimab | Total |
|---|---|---|---|
| Mean | 55.36 (23 to 84) | 54.59 (30 to 79) | 54.85 (23 to 84) |
| Sex: Female, Male(Participants) | Placebo | 700mg Leronlimab | Total |
|---|---|---|---|
| Female | 19 | 32 | 51 |
| Male | 9 | 24 | 33 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 700mg Leronlimab | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 18 | 28 |
| Not Hispanic or Latino | 17 | 35 | 52 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 700mg Leronlimab | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 18 | 28 |
| Not Hispanic or Latino | 17 | 35 | 52 |
| Unknown or Not Reported | 1 | 3 | 4 |
| Region of Enrollment(participants) | Placebo | 700mg Leronlimab | Total |
|---|---|---|---|
| United States | 28 | 56 | 84 |
| COVID SYMPTOMS SCORE(Participants) | Placebo | 700mg Leronlimab | Total |
|---|---|---|---|
| Baseline symptom score less than or equal to 4 | 16 | 29 | 45 |
| Baseline symptom score greater than 4 | 12 | 27 | 39 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2020 to primary completion in Jul 2020, 3 months.
Results were first posted in Jan 2023, 2 years 5 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leronlimab